Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Arnold S. Freedman, MD


Medical Oncology

Make an Appointment

Physician

  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • CAR T-cell therapy
  • Chronic lymphocytic leukemia
  • Hodgkin disease
  • Lymphoma
  • Stem cell/bone marrow transplantation

Diseases Treated

  • Leukemia, Chronic Lymphocytic (CLL)
  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin

Contact Information

  • Appointments617-632-6246 (new)
    617-582-9086 (follow-up)
  • Office Phone Number617-582-9086
  • Fax617-632-6590

Bio

Dr. Freedman is a Professor of Medicine at Harvard Medical School, a member of Dana-Farber Cancer Institute's Department of Medical Oncology, and an attending physician at Brigham and Women's Hospital. Dr. Freedman has focused on clinical and laboratory research in non-Hodgkin's lymphomas. A graduate of Brandeis University, Dr. Freedman received his M.D. from University of Massachusetts Medical School, and came to Dana-Farber as a fellow in medical oncology in 1982. Dr. Freedman's research interests have focused on the development of new therapies for non-Hodgkin's lymphoma. This includes efforts are toward enhancing the effects of antibody based therapies and understanding how the tumor microenvironment can be manipulated in the treatment of lymphomas.

Board Certification:

  • Internal Medicine, 1982
  • Medical Oncology, 1985

Fellowship:

  • Dana-Farber Cancer Institute, Hematology & Oncology

Residency:

  • Memorial Hospital, Worcester, Internal Medicine

Medical School:

  • University of Massachusetts Medical School

Research

Non-Hodgkin's Lymphomas: Biology and New Therapies

In our laboratory, we used cDNA arrays to compare the gene expression of germinal center (GC) B cells with follicular lymphoma (FL) cells, and confirmed differentially expressed genes by qRT-PCR. Among the genes upregulated in FL were cell cycle regulator proteins CDK10, p120, p21CIP1, and p16INK4a; transcription factors/regulators Pax-5 and Id-2; and genes involved in cell-cell interactions: TNF-alpha, IL-2R,-g and IL-4R. We also demonstrated that cytogenetic changes in FL cells correlates with the altered expression of some of these genes at their known loci. These findings provide a basis for future studies of the pathogenesis and pathophysiology of follicular lymphoma, and may lead to the identification of potential therapeutic targets as well as antigens for immunotherapeutic strategies. Based upon our array studies and other work, we are focusing on TNF-alpha, which is overexpressed by FL cells, as a therapeutic target in FL. TNF-alpha upregulates expression of adhesion molecules, cytokines, and chemokines that are critical to interactions between FL cells and follicular dendritic cells (FDC). We are currently conducting a clinical trial of etanercept - which binds to TNF-alpha, reducing its biological activities - in patients with relapsed and refractory follicular lymphoma, and also evaluating a variety of surrogate markers of the microenvironment and T cell function in these patients.In other research, we are attempting to modulate the effects of the anti-CD20 monoclonal antibody (mAb) rituximab. We completed a trial of low dose IL-2 with rituximab in which the numbers of natural killer cells increased in the peripheral blood of treated patients. We have also investigated the combination of rituximab with immunostimulatory DNA sequences (ISS), which enhance antigen presentation and costimulatory molecule expression, stimulate dendritic cell maturation, and induce cytokines, resulting in increased cell-mediated cytotoxicity. Through these effects on both the adaptive and innate immune response, ISS are excellent candidates to enhance the cytotoxicity of mAbs such as rituximab. We completed a phase I study of 1018 ISS in combination with rituximab in patients with relapsed non-Hodgkin's lymphoma (NHL), demonstrating safety and biological activity. Given this favorable data, we plan to test the efficacy of combination immunotherapy in a phase II study in patients with relapsed follicular NHL, and to further analyze the immunologic effects of this combination in vitro and in vivo.

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98.
View in: PubMed

A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481.
View in: PubMed

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
View in: PubMed

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
View in: PubMed

Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020 03; 95(3):316-327.
View in: PubMed

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
View in: PubMed

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
View in: PubMed

Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clin Infect Dis. 2019 01 07; 68(2):247-255.
View in: PubMed

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs. 2018 10; 36(5):869-876.
View in: PubMed

Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018 Feb; 93(2):296-305.
View in: PubMed

Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. Dis Esophagus. 2017 02 01; 30(2):1-8.
View in: PubMed

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
View in: PubMed

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. Curr Hematol Malig Rep. 2016 06; 11(3):218-23.
View in: PubMed

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95.
View in: PubMed

Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol. 2015 Dec; 90(12):1171-8.
View in: PubMed

Rethinking Prognosis and Therapy for Follicular Lymphoma. J Clin Oncol. 2015 Aug 10; 33(23):2489-91.
View in: PubMed

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
View in: PubMed

Is observation dead in follicular lymphoma? Still appropriate. J Natl Compr Canc Netw. 2015 Mar; 13(3):367-70.
View in: PubMed

Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica. 2014 Sep; 99(9):1421-32.
View in: PubMed

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma. 2015 Apr; 56(4):993-8.
View in: PubMed

Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. PLoS One. 2014; 9(7):e101685.
View in: PubMed

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol. 2014 Jun 10; 32(17):1797-803.
View in: PubMed

Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol. 2014 Apr; 89(4):429-36.
View in: PubMed

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol. 2014 Jan; 164(2):258-65.
View in: PubMed

One size does not fit all in follicular lymphoma. J Clin Oncol. 2013 Sep 20; 31(27):3307-8.
View in: PubMed

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6.
View in: PubMed

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
View in: PubMed

First-line treatment of indolent lymphoma: axing CHOP? Lancet. 2013 Apr 06; 381(9873):1163-5.
View in: PubMed

Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):121-7.
View in: PubMed

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17.
View in: PubMed

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013 Apr; 98(4):615-9.
View in: PubMed

Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol. 2012 Oct; 87(10):988-95.
View in: PubMed

Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol. 2012 Sep; 24(5):475-9.
View in: PubMed

Primary bone lymphoma involving bilateral tibia. Am J Hematol. 2012 Sep; 87(9):924-5.
View in: PubMed

Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802.
View in: PubMed

Germline copy number variation associated with Mendelian inheritance of CLL in two families. Leukemia. 2012 Jul; 26(7):1710-3.
View in: PubMed

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6.
View in: PubMed

Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):277-83.
View in: PubMed

Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol. 2011 Sep; 86(9):768-75.
View in: PubMed

Expression of mesenchyme-specific gene signatures by follicular dendritic cells: insights from the meta-analysis of microarray data from multiple mouse cell populations. Immunology. 2011 Aug; 133(4):482-98.
View in: PubMed

Early initial therapy of advanced follicular lymphoma: the need for vigilance. Leuk Lymphoma. 2011 Mar; 52(3):355-7.
View in: PubMed

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011 Apr; 52(4):587-96.
View in: PubMed

(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9.
View in: PubMed

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-1613.
View in: PubMed

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010 Nov; 24(11):1972-5.
View in: PubMed

Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov; 151(4):336-45.
View in: PubMed

Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol. 2010 Jul; 177(1):377-86.
View in: PubMed

Epstein-barr virus-associated diffuse large B-cell lymphoma in an immunocompetent woman. J Clin Oncol. 2010 Feb 10; 28(5):e75-8.
View in: PubMed

ASCT in follicular lymphoma. Nat Rev Clin Oncol. 2009 Jul; 6(7):380-2.
View in: PubMed

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 Aug; 146(3):282-91.
View in: PubMed

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009 Jun 20; 27(18):3036-43.
View in: PubMed

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 Jun; 145(6):741-8.
View in: PubMed

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
View in: PubMed

Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia. 2008 Oct; 22(10):1966-9.
View in: PubMed

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. Br J Haematol. 2008 Nov; 143(3):361-8.
View in: PubMed

Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol. 2008 Dec; 19(12):2043-7.
View in: PubMed

Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.
View in: PubMed

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
View in: PubMed

Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma. Semin Hematol. 2008 Apr; 45(2):85-9.
View in: PubMed

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1057-65.
View in: PubMed

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007 Jun 20; 25(18):2554-9.
View in: PubMed

Novel presentation of intraneural nodular fasciitis of the sciatic nerve. J Peripher Nerv Syst. 2007 Mar; 12(1):61-3.
View in: PubMed

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr Treat Options Oncol. 2006 Jul; 7(4):276-84.
View in: PubMed

Inhibiting TNFa with etanercept in relapsed/refractory follicular lymphoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):17525.
View in: PubMed

Non-transplant-related treatment options in follicular lymphoma. Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 1):53-8.
View in: PubMed

CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy. 2006; 8(4):399-407.
View in: PubMed

Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature. Leuk Lymphoma. 2005 Nov; 46(11):1663-6.
View in: PubMed

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
View in: PubMed

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005 Apr 01; 23(10):2208-14.
View in: PubMed

Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program. 2005; 314-20.
View in: PubMed

TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia. 2004 Dec; 18(12):2015-25.
View in: PubMed

B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol. 2004 Dec; 5(12):711-7.
View in: PubMed

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15; 105(2):489-95.
View in: PubMed

Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Am J Clin Pathol. 2004 May; 121(5):701-8.
View in: PubMed

Integrins regulate survival of pre-B-ALL cells through differential IAP and caspase-7 ubiquitination and degradation. Leukemia. 2004 Apr; 18(4):873-5.
View in: PubMed

An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol. 2004 Mar; 16(2):106-13.
View in: PubMed

Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
View in: PubMed

Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma. 2004 Feb; 45(2):315-20.
View in: PubMed

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leuk Res. 2004 Feb; 28(2):139-47.
View in: PubMed

Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003 Oct; 32(7):681-6.
View in: PubMed

Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol. 2003 Sep; 122(5):745-59.
View in: PubMed

Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion. 2003 May; 43(5):614-21.
View in: PubMed

CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol. 2002 Nov; 119(2):492-5.
View in: PubMed

Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood. 2003 Feb 01; 101(3):1118-27.
View in: PubMed

The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk Lymphoma. 2002 Aug; 43(8):1663-71.
View in: PubMed

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34.
View in: PubMed

Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44.
View in: PubMed

Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002 Jan 01; 99(1):282-9.
View in: PubMed

Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2002; 8(8):429-34.
View in: PubMed

Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma. 2002 Jan; 43(1):115-9.
View in: PubMed

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.
View in: PubMed

Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001 Dec 03; 194(11):1625-38.
View in: PubMed

MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001 Dec; 115(3):554-62.
View in: PubMed

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
View in: PubMed

The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2001; 7(8):446-53.
View in: PubMed

Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment. Exp Hematol. 2000 Dec; 28(12):1325-33.
View in: PubMed

Functional effects of TNF and lymphotoxin alpha1beta2 on FDC-like cells. Cell Immunol. 2000 Aug 01; 203(2):134-43.
View in: PubMed

High-dose therapy for follicular lymphoma. Oncology (Williston Park). 2000 Mar; 14(3):321-6, 329; discussion 330-2, 338.
View in: PubMed

Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33.
View in: PubMed

Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
View in: PubMed

A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999 Sep; 5(9):2392-8.
View in: PubMed

High-dose therapy and stem cell transplantation in follicular lymphoma. Ann Hematol. 1999 May; 78(5):203-11.
View in: PubMed

Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol. 1999 Apr; 36(2):209-16.
View in: PubMed

PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet. 1999 Feb; 8(2):185-93.
View in: PubMed

Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8.
View in: PubMed

Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998 Jun 15; 91(12):4496-503.
View in: PubMed

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.
View in: PubMed

High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Jan; 28(3-4):219-30.
View in: PubMed

Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998 Jan 01; 91(1):244-51.
View in: PubMed

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
View in: PubMed

Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001.
View in: PubMed

Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 1997 Dec; 28(1-2):65-72.
View in: PubMed

Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997 Nov 15; 90(10):4212-21.
View in: PubMed

The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1. J Biol Chem. 1997 Aug 08; 272(32):19719-24.
View in: PubMed

Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2. J Biol Chem. 1997 Jun 20; 272(25):15636-41.
View in: PubMed

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47.
View in: PubMed

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr; 3(1):11-7.
View in: PubMed

Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6.
View in: PubMed

The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta1-integrin stimulation in B cells and binds to p130cas. J Biol Chem. 1997 Jan 03; 272(1):228-32.
View in: PubMed

Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50.
View in: PubMed

High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6.
View in: PubMed

Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells. Blood. 1996 Mar 01; 87(5):1855-61.
View in: PubMed

Cell surface antigens in leukemias and lymphomas. Cancer Invest. 1996; 14(3):252-76.
View in: PubMed

Expression of vascular cell adhesion molecule-1 by follicular dendritic cells. Leuk Lymphoma. 1995 Jul; 18(3-4):259-64.
View in: PubMed

Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995 Mar; 17(1-2):87-93.
View in: PubMed

Role of follicular dendritic cells in the regulation of B cell proliferation. Curr Top Microbiol Immunol. 1995; 201:83-92.
View in: PubMed

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994 Dec; 12(12):2535-42.
View in: PubMed

Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood. 1994 Jun 15; 83(12):3800-7.
View in: PubMed

A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood. 1994 May 01; 83(9):2707-14.
View in: PubMed

Selective ablation of rat brain tumors by boron neutron capture therapy. Int J Radiat Oncol Biol Phys. 1994 Mar 30; 28(5):1067-77.
View in: PubMed

Adhesion of follicular lymphoma cells to lymphoid germinal centers--a potential mechanism of tumor cell homing following autologous transplantation. Leuk Lymphoma. 1994 Mar; 13(1-2):47-52.
View in: PubMed

In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood. 1994 Feb 01; 83(3):793-8.
View in: PubMed

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol. 1994; 5 Suppl 2:143-6.
View in: PubMed

Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993 Oct 15; 82(8):2568-76.
View in: PubMed

Expression and function of adhesion receptors on normal B cells and B cell non-Hodgkin's lymphomas. Semin Hematol. 1993 Oct; 30(4):318-28.
View in: PubMed

Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? J Clin Oncol. 1993 Oct; 11(10):1841-3.
View in: PubMed

Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993 Sep; 12(3):243-51.
View in: PubMed

Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993 Aug 15; 82(4):1366-76.
View in: PubMed

Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood. 1993 Jun 15; 81(12):3449-57.
View in: PubMed

Developments in purging in autotransplantation. Hematol Oncol Clin North Am. 1993 Jun; 7(3):687-715.
View in: PubMed

Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol. 1993 May; 11(5):931-6.
View in: PubMed

Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood. 1993 May 01; 81(9):2263-71.
View in: PubMed

Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood. 1993 Apr 01; 81(7):1903-8.
View in: PubMed

Stimulation of protein tyrosine phosphorylation in human B cells after ligation of the beta 1 integrin VLA-4. J Immunol. 1993 Mar 01; 150(5):1645-52.
View in: PubMed

Follicular dendritic cells inhibit human B-lymphocyte proliferation. Blood. 1992 Sep 01; 80(5):1284-8.
View in: PubMed

Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood. 1992 Aug 15; 80(4):1083-9.
View in: PubMed

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992 Jul; 10(7):1191-200.
View in: PubMed

Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 01; 79(9):2229-36.
View in: PubMed

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood. 1992 Feb 01; 79(3):576-85.
View in: PubMed

The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. Blood. 1992 Jan 15; 79(2):489-94.
View in: PubMed

Follicular non-Hodgkin's lymphoma cell adhesion to normal germinal centers and neoplastic follicles involves very late antigen-4 and vascular cell adhesion molecule-1. Blood. 1992 Jan 01; 79(1):206-12.
View in: PubMed

All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood. 1991 Dec 15; 78(12):3275-80.
View in: PubMed

Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991 Dec; 52(6):1014-9.
View in: PubMed

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991 Nov 28; 325(22):1525-33.
View in: PubMed

Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol. 1991 Oct 15; 137(2):429-37.
View in: PubMed

Immunologic markers in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 1991 Oct; 5(5):871-89.
View in: PubMed

Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4+ T cells. Cell Immunol. 1991 Oct 01; 137(1):150-63.
View in: PubMed

B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A. 1991 Aug 01; 88(15):6575-9.
View in: PubMed

Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991 Jun 20; 324(25):1773-8.
View in: PubMed

Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991 Jun 01; 77(11):2524-9.
View in: PubMed

Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood. 1991 Apr 15; 77(8):1837-44.
View in: PubMed

Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia. 1991 Apr; 5(4):300-8.
View in: PubMed

Cellular interactions within the germinal centre. Res Immunol. 1991 Mar-Apr; 142(3):232-6.
View in: PubMed

Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991 Feb 15; 77(4):712-20.
View in: PubMed

B-cell monoclonal antibodies and their use in clinical oncology. Cancer Invest. 1991; 9(1):69-84.
View in: PubMed

Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991 Jan; 7(1):23-33.
View in: PubMed

Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1990 Nov; 6(5):329-31.
View in: PubMed

A chronic "postinfectious" fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6. J Clin Immunol. 1990 Nov; 10(6):335-44.
View in: PubMed

Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science. 1990 Aug 31; 249(4972):1030-3.
View in: PubMed

Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia. Blood. 1990 Jul 01; 76(1):142-9.
View in: PubMed

T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood. 1990 Jul 01; 76(1):235-44.
View in: PubMed

Further characterization of prolymphocytic leukemia cells as a tumor of activated B cells. Am J Hematol. 1990 Jul; 34(3):181-5.
View in: PubMed

Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol. 1990 May; 8(5):784-91.
View in: PubMed

Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A. 1990 Apr; 87(7):2770-4.
View in: PubMed

mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells. Immunology. 1990 Apr; 69(4):531-5.
View in: PubMed

Immunobiology of chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):405-29.
View in: PubMed

Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol. 1990 Jan 15; 144(2):532-40.
View in: PubMed

Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 1990 Jan 01; 75(1):296-304.
View in: PubMed

Molecular cloning of the B-cell-restricted activation antigen B7 identifies a new member of the immunoglobulin gene family. Leukocyte Typing IV. 1990; 141-2.

The relationship of chronic lymphocytic leukemia to normal activated B cells. Leuk Lymphoma. 1990; 1(5-6):293-300.
View in: PubMed

1989, Isolation and phenotypic characterization of follicular dendritic cells from human tonsil. Leukocyte Typing IV. 1990; 185.

Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989 Dec 01; 143(11):3543-7.
View in: PubMed

Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood. 1989 Nov 01; 74(6):2203-11.
View in: PubMed

Activation primes human B lymphocytes to respond to heat shock. J Exp Med. 1989 Nov 01; 170(5):1763-8.
View in: PubMed

B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989 Oct 15; 143(8):2714-22.
View in: PubMed

Immunophenotypic profile of CNS lymphoma: a review of eighteen cases. J Neurooncol. 1989 Sep; 7(3):249-54.
View in: PubMed

Autologous bone-marrow transplantation in non-Hodgkin's lymphomas. Biochim Biophys Acta. 1989 Jul 28; 989(1):11-24.
View in: PubMed

Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med. 1989 Jun 01; 169(6):2043-58.
View in: PubMed

Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989 May; 4(3):239-45.
View in: PubMed

Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989 May; 83(5):1512-8.
View in: PubMed

Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol. 1989 May; 19(5):849-55.
View in: PubMed

Autologous bone marrow transplantation in low grade non-Hodgkin's lymphoma. Autologous Bone Marrow Transplantation IV, Proceedings of the Fourth International Symposium. 1989; 327-30.

Autologous bone marrow transplantation therapy for multiple myeloma. Eur J Haematol Suppl. 1989; 51:157-63.
View in: PubMed

Studies of in vitro activated CD5+ B cells. Blood. 1989 Jan; 73(1):202-8.
View in: PubMed

Pre-exposure of human B cells to recombinant IL-1 enhances subsequent proliferation. J Immunol. 1988 Nov 15; 141(10):3398-404.
View in: PubMed

Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Cancer Treat Res. 1988; 38:265-83.
View in: PubMed

B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol. 1987 Nov 15; 139(10):3260-7.
View in: PubMed

B cell development in chronic lymphocytic leukemia. Semin Hematol. 1987 Oct; 24(4):230-9.
View in: PubMed

Normal cellular counterparts of B cell chronic lymphocytic leukemia. Blood. 1987 Aug; 70(2):418-27.
View in: PubMed

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11; 316(24):1499-505.
View in: PubMed

Cell surface markers in hematologic malignancies. Semin Oncol. 1987 Jun; 14(2):193-212.
View in: PubMed

Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. Cell Immunol. 1987 May; 106(2):355-65.
View in: PubMed

Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
View in: PubMed

In vitro applications of monoclonal antibodies for bone marrow transplantation. Leukocyte Typing III. 1987; 938-43.

Phenotypic changes following in vitro activation of human B cells: Analysis of Third International Workshop of B cell and Activation Antigen Panels. Leukocyte Typing III. 1987; 554-5.

Expression of B cell activation antigens on normal and malignant B cells. Leukemia. 1987 Jan; 1(1):9-15.
View in: PubMed

Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
View in: PubMed

Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of the role of autocrine effects on B-cell proliferation and of T-cell help in B-cell differentiation. Cell Immunol. 1986 Apr 15; 99(1):228-40.
View in: PubMed

The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985 Aug; 135(2):973-9.
View in: PubMed

B5, a new B cell-restricted activation antigen. J Immunol. 1985 Apr; 134(4):2228-35.
View in: PubMed

Immunologic heterogeneity of diffuse large cell lymphoma. Blood. 1985 Mar; 65(3):630-7.
View in: PubMed

Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. J Immunol. 1985 Mar; 134(3):1516-23.
View in: PubMed

Phenotypic changes occuring during in vitro activation of human splenic B lymphocytes. Leukocyte Typing II. 1985; 2:429-41.

Antigenic changes of the B cell panel of the Second International Workshop on Human Leukocyte Differentiation Antigens with in vitro activation. Leukocyte Typing II. 1985; 2:443-54.

Radionuclide ejection fraction in doxorubicin cardiotoxicity. Cancer Treat Rep. 1981 Jul-Aug; 65(7-8):629-38.
View in: PubMed

Maximizing your corporate pension plan. Dent Econ. 1979 Nov; 69(11):58-61.
View in: PubMed

The Arkansas granny midwife: a sociological profile. J Ark Med Soc. 1974 Oct; 71(5):169-70.
View in: PubMed

The passing of the Arkansas granny midwife. Ky Folkl Rec. 1974; 20(4):101-3.
View in: PubMed

Knowledge of heart disease in a rural community. J Ark Med Soc. 1967 Nov; 64(6):203-7.
View in: PubMed

Cancer chemotherapy. Med J Aust. 1961 Dec 09; 48(2):958-9.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana Building D1B30
Boston, MA 02215
Get Directions

Ratings

Top